[Zurück zum
Forschungsbericht]

A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase 2 trial to investigate the safety and efficacy of secukinumab (AIN457) in patients with giant cell arteritis - (MRT Substudie) - CAIN457ADE11C

Projektbeschreibung:
A randomized, parallel-group, double-blind, placebo-controlled, multicenter phase 2 trial to investigate the safety and efficacy of secukinumab (AIN457) in patients with giant cell arteritis - (MRT Substudie) - CAIN457ADE11C
Projektlaufzeit:
Projektbeginn: 2019
Projektende: 2021
Projektleitung:
Meckel S, Bley T

Bley T (Würzburg)


Aktueller Forschungsbericht